Prognostic markers in osteosarcoma

References

• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int. J. Cancer125(1), 229–234 (2009).
   PubMed Web of Science ®Google Scholar
• Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med.341(5), 342–352 (1999).
   PubMed Web of Science ®Google Scholar
• Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Principles and Practices of Pediatric Oncology (5th edition). Pizzo PA, Poplack DG (Eds). Lippincott Williams & Wilkins, PA, USA, 1074–1115 (2006).
   Google Scholar
• Wu PK, Chen WM, Chen CF, Lee OK, Haung CK, Chen TH. Primary osteogenic sarcoma with pulmonary metastasis, clinical results and prognostic factors in 91 patients. Jpn J. Clin. Oncol.39(8), 514–522 (2009).
   PubMed Web of Science ®Google Scholar
• Bramer JA, Van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma, a systematic review. Eur. J. Surg. Oncol.35(10), 1030–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy, 15-year experience in 789 patients treated at a single institution. Cancer106(5), 1154–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk, an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol.20(3), 776–790 (2002).
   PubMed Web of Science ®Google Scholar
• Pakos EE, Nearchou AD, Grimer RJ et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur. J. Cancer45(13), 2367–2375 (2009).
   PubMed Web of Science ®Google Scholar
• Ozaki T, Flege S, Liljenqvist U et al. Osteosarcoma of the spine, experience of the Cooperative Osteosarcoma Study Group. Cancer94(4), 1069–1077 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis, experience of the Cooperative Osteosarcoma study group. J. Clin. Oncol.21(2), 334–341 (2003).
   PubMed Web of Science ®Google Scholar
• Bieling P, Rehan N, Winkler P et al. Tumor size and prognosis in aggressively treated osteosarcoma. J. Clin. Oncol.14(3), 848–858 (1996).
   PubMed Web of Science ®Google Scholar
• Rehan N, Bieling P, Winkler P et al. The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy. Klin. Padiatr.205(4), 200–209 (1993).
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim MS, Kim DH et al. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr. Blood Cancer50(2), 195–200 (2008).
   PubMed Web of Science ®Google Scholar
• Munajat I, Zulmi W, Norazman MZ, Wan Faisham WI. Tumour volume and lung metastasis in patients with osteosarcoma. J. Orthop. Surg. (Hong Kong)16(2), 182–185 (2008).
   Google Scholar
• Aljubran AH, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults, survival analysis with and without lung metastases. Ann. Oncol.20(6), 1136–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Mercuri M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41–60 years, outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop.78(3), 377–384 (2007).
   PubMed Web of Science ®Google Scholar
• Harting MT, Lally KP, Andrassy RJ et al. Age as a prognostic factor for patients with osteosarcoma, an analysis of 438 patients. J. Cancer Res. Clin. Oncol. DOI 10.1007/s00432-009-0690-5 (2009) (Epub ahead of print).
   Google Scholar
• Bacci G, Balladelli A, Palmerini E et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients, the Rizzoli Institute experience. J. Pediatr. Hematol. Oncol.30(12), 908–912 (2008).
   Google Scholar
• Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. Relat. Res.153, 106–120 (1980).
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID et al. Osteosarcoma. In: AJCC cancer staging manual. Springer, NY, USA 213–220 (2002).
   Google Scholar
• Kager L, Zoubek A, Kastner U et al. Skip metastases in osteosarcoma, experience of the Cooperative Osteosarcoma Study group. J. Clin. Oncol.24(10), 1535–1541 (2006).
   PubMed Web of Science ®Google Scholar
• Sajadi KR, Heck RK, Neel MD et al. The incidence and prognosis of osteosarcoma skip metastases. Clin. Orthop. Relat. Res.426, 92–96 (2004).
   Google Scholar
• Ferrari S, Briccoli A, Mercuri M et al. Late relapse in osteosarcoma. J. Pediatr. Hematol. Oncol.28(7), 418–422 (2006).
   PubMed Web of Science ®Google Scholar
• Bacci G, Bertoni F, Longhi A et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer97(12), 3068–3075 (2003).
   PubMed Web of Science ®Google Scholar
• Bacci G, Mercuri M, Longhi A et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur. J. Cancer41(14), 2079–2085 (2005).
   PubMed Web of Science ®Google Scholar
• Grimer RJ, Taminiau AM, Cannon SR; Surgical Subcommittee of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J. Bone Joint Surg. Br.84(3), 395–400 (2002).
   PubMedGoogle Scholar
• Barr RD, Wunder JS. Bone and soft tissue sarcomas are often curable – but at what cost? A call to arms (and legs). Cancer115(18), 4046–4054 (2009).
   PubMed Web of Science ®Google Scholar
• Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur. J. Cancer43(13), 1944–1951 (2007).
   PubMed Web of Science ®Google Scholar
• González-Billalabeitia E, Hitt R, Fernández J, Conde E et al. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. Clin. Transl. Oncol.11(7), 479–483 (2009).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Ferrari S et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity, experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori90(5), 478–484 (2004).
   Google Scholar
• Bacci G, Picci P, Orlandi M et al. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori73(4), 331–336 (1987).
   Google Scholar
• Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur. J. Cancer41(18), 2846–2852 (2005).
   PubMed Web of Science ®Google Scholar
• Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma, a critical review. J. Clin. Oncol.12(2), 423–431(1994).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Briccoli A, Mercuri M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity, intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J. Pediatr. Hematol. Oncol.25(11), 845–853 (2003).
   Google Scholar
• Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol.19(4), 341–346 (2007).
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst. Rev.21(1), CD006325 (2009).
   Google Scholar
• Serra M, Pasello M, Manara MC et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int. J. Oncol.29(6), 1459–1468 (2006).
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Serra M et al. P-glycoprotein expression in osteosarcoma, a basis for risk-adapted adjuvant chemotherapy. J. Orthop. Res.17(5), 629–632 (1999).
   Google Scholar
• Schwartz CL, Gorlick R, Teot L et al. Multiple drug resistance in osteogenic sarcoma, INT0133 from the Children’s Oncology Group. J. Clin. Oncol.25(15), 2057–2062 (2007).
   PubMed Web of Science ®Google Scholar
• Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer98(3), 581–589 (2003).
   PubMed Web of Science ®Google Scholar
• Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res.466(9), 2114–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol. Ther.8(6), 543–552 (2009).
   PubMed Web of Science ®Google Scholar
• Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol.34(5), 1381–1386 (2009).
   PubMed Web of Science ®Google Scholar
• Oda Y, Sakamoto A, Shinohara N et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin. Cancer Res.4(9), 2273–2277 (1998).
   PubMed Web of Science ®Google Scholar
• Caronia D, Patiño-García A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J.9(5), 347–353 (2009).
   PubMed Web of Science ®Google Scholar
• Mintz MB, Sowers R, Brown KM et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer.65(5), 1748–1754 (2005).
   Google Scholar
• Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod. Pathol.20(10), 1085–1094 (2007).
   PubMed Web of Science ®Google Scholar
• Huang Y, Lin Z, Zhuang J, Chen Y, Lin J. Prognostic significance of a V integrin and VEGF in osteosarcoma after chemotherapy. Onkologie31(10), 535–540 (2008).
   Google Scholar
• Mikulic D, Ilic I, Cepulic M et al. Tumor angiogenesis and outcome in osteosarcoma. Pediatr. Hematol. Oncol.21(7), 611–619 (2004).
   PubMed Web of Science ®Google Scholar
• Wang D, Chen L, Gao F. Correlation of tumor microvessel density with prognosis in osteogenic sarcoma. Zhonghua Bing Li Xue Za Zhi26(5), 266–269 (1997).
   Google Scholar
• Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin. Orthop. Relat. Res.448, 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol. Rep.16(1), 17–23 (2006).
   Google Scholar
• Sznurkowska K, Lenckowski R, Popadiuk S, Szumera M, Renke J, Korzon M. Assessment of angiogenesis in children’s osteosarcoma. Med. Wieku Rozwoj.10(3 Pt 1), 737–744 (2006).
   Google Scholar
• Bajpai J, Sharma M, Sreenivas V et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr. Blood Cancer53(6), 1035–1039 (2009).
   PubMedGoogle Scholar
• Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J. Bone Joint Surg. Br.91(6), 784–788 (2009).
   Google Scholar
• Han I, Lee MR, Nam KW, Oh JH, Moon KC, Kim HS. Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Clin. Orthop. Relat. Res.466(9), 2107–2113 (2008).
   Google Scholar
• Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma, a meta-analysis. Clin. Cancer Res.10(18 Pt 1), 6208–6214 (2004).
   PubMed Web of Science ®Google Scholar
• Wunder JS, Gokgoz N, Parkes R et al.TP53 mutations and outcome in osteosarcoma, a prospective, multicenter study. J. Clin. Oncol.23(7), 1483–1490 (2005).
   PubMed Web of Science ®Google Scholar
• Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S. Her-2/neu, p-53, and their coexpression in osteosarcoma. J. Pediatr. Hematol. Oncol.31(4), 245–251 (2009).
   PubMedGoogle Scholar
• Kaseta MK, Gomatos IP, Khaldi L et al. Prognostic value of bax, cytochrome C, and caspase-8 protein expression in primary osteosarcoma. Hybridoma (Larchmt)26(6), 355–362 (2007).
   PubMedGoogle Scholar
• Nedelcu T, Kubista B, Koller A et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J. Cancer Res. Clin. Oncol.134(2), 237–244 (2008).
   PubMed Web of Science ®Google Scholar
• Osaka E, Suzuki T, Osaka S et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem. Cytochem.39(3), 95–100 (2006).
   PubMed Web of Science ®Google Scholar
• Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR. Survivin expression in human osteosarcoma is a marker for survival. Eur. J. Surg. Oncol.29(4), 379–382 (2003).
   PubMed Web of Science ®Google Scholar
• Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br. J. Cancer82(1), 85–87 (2000).
   PubMed Web of Science ®Google Scholar
• Huang J, Zhu B, Lu L et al. The expression of novel gene URG4 in osteosarcoma, correlation with patients’ prognosis. Pathology41(2), 149–154 (2009).
   Web of Science ®Google Scholar
• Liao QD, Zhong D, Chen Q. Protein expression of Skp2 in osteosarcoma and its relation with prognosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban33(7), 606–611 (2008).
   Google Scholar
• Lee WI, Bacchni P, Bertoni F, Maeng YH, Park YK. Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma. Oncol. Rep.12(1), 125–128 (2004).
   PubMed Web of Science ®Google Scholar
• Anninga JK, van de Vijver MJ, Cleton-Jansen AM et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer40(7), 963–970 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai JY, Aviv H, Benevenia J et al. HER-2/neu and p53 in osteosarcoma, an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest.22(1), 16–24 (2004).
   PubMed Web of Science ®Google Scholar
• Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma, a tissue microarray study. Pediatr. Dev. Pathol.8(5), 525–532 (2005).
   PubMed Web of Science ®Google Scholar
• Rakesh Kumar V, Gupta N, Kakkar N, Sharma SC. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J. Cancer Res. Ther.2(1), 20–23 (2006).
   Google Scholar
• Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin. Cancer Res.8(3), 788–793 (2002).
   PubMed Web of Science ®Google Scholar
• Yalçin B, Gedikoglu G, Kutluk T, Varan A, Akyüz C, Büyükpamukçu M. C-erbB-2 expression and prognostic significance in osteosarcoma. Pediatr. Blood Cancer51(2), 222–227 (2008).
   Google Scholar
• Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch D. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab. Invest.84(1), 113–121 (2004).
   PubMed Web of Science ®Google Scholar
• Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin. Orthop. Relat. Res.382, 59–65 (2001).
   PubMedGoogle Scholar
• Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol.17(9), 2781–2788 (1999).
   PubMed Web of Science ®Google Scholar
• Onda M, Matsuda S, Higaki S et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer77(1), 71–78 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J. Pediatr. Hematol. Oncol.25(1), 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• Li YG, Geng X. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur. J. Cancer Care (Engl). (2009) (Epub ahead of print).
   Google Scholar
• Kubo T, Piperdi S, Rosenblum J et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer112(10), 2119–2129 (2008).
   PubMed Web of Science ®Google Scholar
• Wei H, Zhao MQ, Dong W, Yang Y, Li JS. Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J. Int. Med. Res.36(5), 1008–1014 (2008).
   PubMed Web of Science ®Google Scholar
• Khanna C, Khan J, Nguyen P et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res.61(9), 3750–3759 (2001).
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res.65(6), 2406–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Xu-Dong S, Zan S, Shui-er Z et al. Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin. Invest. Med.32(2), E180–E188 (2009).
   Google Scholar
• Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr. Blood Cancer50(4), 752–756 (2008).
   PubMed Web of Science ®Google Scholar
• Salas S, Bartoli C, Deville JL et al. Ezrin and a-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch.451(6), 999–1007 (2007).
   Google Scholar
• Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K. CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett.209(1), 105–110 (2004).
   Google Scholar
• Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin. Orthop. Relat. Res.396, 184–190 (2002).
   Google Scholar
• Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H. Expression of CD44 variants in osteosarcoma. J. Cancer Res. Clin. Oncol.125(11), 646–652 (1999).
   PubMed Web of Science ®Google Scholar
• Nakajima G, Patino-Garcia A, Bruheim S et al. CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics5(1), 37–42 (2008).
   PubMedGoogle Scholar
• Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM. Matrix metalloproteinases participate in osteosarcoma invasion. J. Surg. Res.127(2), 151–156 (2005).
   PubMed Web of Science ®Google Scholar
• Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int. J. Oncol.28(1), 33–42 (2006).
   PubMed Web of Science ®Google Scholar
• Sato J, Yanagawa T, Dobashi Y, Yamaji T, Takagishi K, Watanabe H. Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy, a possible association with autocrine motility factor/phosphoglucose isomerase expression. Clin. Exp. Metastasis25(4), 427–435 (2008).
   Google Scholar
• Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-d-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer115(15), 3519–3525 (2009).
   PubMed Web of Science ®Google Scholar
• Ye Z, Zhu J, Tian M et al. Response of osteogenic sarcoma to neoadjuvant therapy, evaluated by 18F-FDG-PET. Ann. Nucl. Med.22(6), 475–480 (2008).
   Google Scholar
• Bajpai J, Kumar R, Vishnubhatla S, Sharma MC, Bakhshi S. PET-CT in osteosarcoma for chemotherapy response evaluation: correlation with histological necrosis. J. Nucl. Med.50(Suppl. 2), 582 (2009).
   Google Scholar
• Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J. Nucl. Med.50(9), 1435–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Bajpai J, Gamnagatti S, Sreenivas V et al. Role of MRI in osteosarcoma for chemotherapy response evaluation and prediction: correlation with histological necrosis. J. Clin. Oncol.27, 15s (2009).
   Google Scholar
• Uhl M, Saueressig U, Koehler G et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging, preliminary results in osteosarcomas. Pediatr. Radiol.36(12), 1306–1311 (2006).
   Google Scholar
• Hoang BH, Dyke JP, Koutcher JA et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin. Orthop. Relat. Res.426, 32–38 (2004).
   Google Scholar
• Selvarajah S, Yoshimoto M, Ludkovski O et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet. Genome Res.122(1), 5–15 (2008).
   Google Scholar
• Tarkkanen M, Elomaa I, Blomqvist C et al. DNA sequence copy number increase at 8q, a potential new prognostic marker in high-grade osteosarcoma. Int. J. Cancer84(2), 114–121 (1999).
   PubMed Web of Science ®Google Scholar
• Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, Lu Z. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer106(7), 1602–1609 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn. Mol. Pathol.13(2), 81–91 (2004).
   Google Scholar
• Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int. J. Cancer84(5), 489–493 (1999).
   PubMed Web of Science ®Google Scholar
• Maitra A, Roberts H, Weinberg AG, Geradts J. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int. J. Cancer95(1), 34–38 (2001).
   Google Scholar
• Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-b isoform and VEGF in osteosarcoma. Orthopedics28(8), 755–760 (2005).
   Google Scholar
• Gamberi G, Benassi MS, Bohling T et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology55(6), 556–563 (1998).
   PubMed Web of Science ®Google Scholar
• Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch.432(6), 515–519 (1998).
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res.53(1), 16–18 (1993).
   PubMed Web of Science ®Google Scholar
• Kanoe H, Nakayama T, Murakami H et al. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Anticancer Res.18(4A), 2317–2321 (1998).
   PubMedGoogle Scholar
• Maelandsmo GM, Berner JM, Florenes VA et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas – relationship to amplification and mRNA levels of CDK4 and CCND1. Br. J. Cancer72(2), 393–398 (1995).
   PubMedGoogle Scholar
• Haydon RC, Deyrup A, Ishikawa A et al. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer102(4), 338–342 (2002).
   PubMed Web of Science ®Google Scholar
• Sangiorgi L, Gobbi GA, Lucarelli E et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int. J. Cancer95(3), 156–161 (2001).
   PubMed Web of Science ®Google Scholar